Anthony P. Conley, MD

Peer-Reviewed Articles

1. Nelson BE, Janku F, Fu S, Dumbrava EE, Hong DS, Karp DD, Naing A, Rodon J, Tsimberidou AM, Murthy R, Sheth RA, Amaria RN, Conley AP, Damodaran S, Raghav KPS, Carapanceanu N, Singh MP, Carapanceanu V, Pezeshki A, Leontovich AA, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clin Cancer Res 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
2. Traweek RS, Zoghbi M, Lazcano R, Cope BM, Bishop AJ, Farooqi A, Mitra D, Yoder AK, Guadagnolo BA, Ingram DR, Wani K, Shamsutdinova D, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Ratan R, Livingston JA, Nakazawa MS, Araujo DM, Patel S, Ravi V, Conley AP, Zarzour MA, Somaiah N, Roland CL, Nassif Haddad EF. Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma. ESMO Open 10(7):105493, 2025. e-Pub 2025. PMID: 40561658.
3. Tap WD, Cote GM, Burris H, Gore L, Elias A, Beeram M, Conley AP, Gianolio DA, Qu Z, Pandya S, Trent JC. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. Clin Cancer Res 31(11):2108-2114, 2025. e-Pub 2025. PMID: 40100120.
4. Ginn MP, Denu RA, Ingram DR, Wani KM, Lazar AJ, Harrison DJ, Nakazawa MS, Conley AP, Patel S, Livingston JA. TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361368.
5. Torres, MB, Leung, CH, Zoghbi, M, Segura Lazcano, R, Ingram, D, Wani, K, Keung, EZ, Zarzour, MA, Scally, CP, Hunt, KK, Conley, AP, Bishop, AJ, Guadagnolo, BA, Farooqi, AS, Mitra, D, Yoder, A, Nakazawa, MS, Araujo, DM, Livingston, A, Ratan, R, Patel, S, Ravi, V, Lazar, A, Roland, CL, Somaiah, N, Nassif, EF. Dedifferentiated liposarcomas treated with immune checkpoint blockade. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 40370451.
6. Patel RR, Delclos GL, DeSantis SM, Cannell MB, Lupo PJ, Bishop AJ, Lazar AJ, Lin PP, Benjamin RS, Patel SR, Ludwig J, Ravi V, Livingston JA, Somaiah N, Zarzour MA, Conley AP, Araujo DM. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma?. Am J Clin Oncol 48(1):21-27, 2025. e-Pub 2025. PMID: 39224003.
7. Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, Araujo DM, Somaiah N, Ravi V, Nassif EF, Roland CL, Lazar AJ, Guadagnolo BA, Harrison DJ, Benjamin RS, Patel SR, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors, 2024. PMID: 39105190.
8. Awad A, Pal K, Yevich S, Kuban JD, Tam A, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Ratan R, Roland CL, Keung EZ, Huang SY, Sheth RA. Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver. Cancer 130(15):2703-2712, 2024. e-Pub 2024. PMID: 38642369.
9. Pal K, Awad A, Yevich S, Kuban JD, Tam A, Huang SY, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo D, Zarzour MA, Ravin R, Roland CL, Keung EZ, Sheth RA. Safety and efficacy of percutaneous cryoablation for recurrent or metastatic soft tissue sarcoma in adult patients. AJR AM J Roentgenol 223(4), 2024. PMID: 39082849.
10. Cote GM, Conley AP, Attia S, Van Tine BA, Seetharam M, Chen YL, Gafoor Z, Heery C, Pico-Navarro C, Adams T. A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. Cancer 130(22):3845-3854, 2024. PMID: 38985843.
11. Nakazawa MS, Silverman IM, Rimkunas V, Veloso A, Glodzik D, Johnson A, Ohsumi TK, Patel SR, Conley AP, Roland CL, Soliman PT, Beird HC, Wu CC, Ingram DR, Lazcano R, Song D, Wani KM, Lazar AJ, Yap TA, Wang WL, Livingston JA. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas. Mol Cancer Ther 23(7):1057-1065, 2024. e-Pub 2024. PMID: 38561019.
12. Conley A, Larson C, Oronsky B, Stirn M, Caroen S, Reid TR. Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing. J Immunother Cancer, 2024. e-Pub 2024. PMID: 38886116.
13. Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-grade pleomorphic sarcomas treated with immune checkpoint blockade: the MD Anderson Cancer Center Experience. Cancers, 2024. e-Pub 2024. PMID: 38730715.
14. Denu RA, Joseph CP, Urquiola ES, Byrd PS, Yang RK, Ratan R, Zarzour MA, Conley AP, Araujo DM, Ravi V, Nassif Haddad EF, Nakazawa MS, Patel S, Wang WL, Lazar AJ, Somaiah N. Utility of clinical next generation sequencing tests in KIT/PDGFRA/SDH Wild-type gastrointestinal stromal tumors. Cancers 16(9):1707, 2024. e-Pub 2024. PMID: 38730662.
15. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
16. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
17. Conley AP, Roland CL, Bessudo A, Gastman BR, Villaflor VM, Larson C, Reid TR, Caroen S, Oronsky B, Stirn M, Williams J, Burbano E, Coyle A, Barve MA, Wagle N, Abrouk N, Kesari S. BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. Cancer Gene Ther 31(4):517-526, 2024. e-Pub 2024. PMID: 38146006.
18. Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473266.
19. Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJ. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys. e-Pub 2023. PMID: 37914142.
20. Beird HC, Wu CC, Nakazawa M, Ingram D, Daniele JR, Lazcano R, Little L, Davies C, Daw NC, Wani K, Wang WL, Song X, Gumbs C, Zhang J, Rubin B, Conley A, Flanagan AM, Lazar AJ, Futreal PA. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. HGG Adv 4(4):100224, 2023. e-Pub 2023. PMID: 37593416.
21. Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med 389(10):911-921, 2023. e-Pub 2023. PMID: 37672694.
22. Sherry AD, Maroongroge S, De B, Amini B, Conley AP, Bishop AJ, Wang C, Beckham T, Tom M, Briere T, Li J, Yeboa DN, McAleer MF, North R, Tatsui CE, Rhines LD, Ghia AJ. Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery. J Neurooncol 164(2):377-386, 2023. e-Pub 2023. PMID: 37667065.
23. Denu RA, Moyers JT, Gouda MA, Conley A, Lazar AJ, Subbiah V. The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implications. Clin Cancer Res. e-Pub 2023. PMID: 37643131.
24. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
25. Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP. Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. e-Pub 2023. PMID: 37265425.
26. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
27. Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2023. PMID: 36151848.
28. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
29. Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza SM, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley AP. Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes. Clin Cancer Res 29(23):4844-4852, 2023. e-Pub 2023. PMID: 37747813.
30. Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother 45(8):374-378, 2022. e-Pub 2022. PMID: 35943386.
31. Oronsky B, Gastman B, Conley AP, Reid C, Caroen S, Reid T. Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot. Cancers (Basel) 14(4701), 2022. e-Pub 2022. PMID: 36230621.
32. Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing A. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer 128(18):3383-3391, 2022. e-Pub 2022. PMID: 35792683.
33. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
34. D'Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, Kelly C, Keohan ML, Movva S, Thornton K, Rosenbaum E, Chi P, Nacev B, Chan JE, Slotkin EK, Kiesler H, Adamson T, Ling L, Rao P, Patel S, Livingston JA, Singer S, Agaram NP, Antonescu CR, Koff A, Erinjeri JP, Hwang S, Qin LX, Donoghue MTA, Tap WD. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun 13(1):3477, 2022. e-Pub 2022. PMID: 35710741.
35. Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
36. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
37. Rubino F, Alvarez-Breckenridge C, Akdemir K, Conley AP, Bishop AJ, Wang WL, Lazar AJ, Rhines LD, DeMonte F, Raza SM. Prognostic Molecular Biomarkers in Chordomas: A Systematic Review and Identification of Clinically usable Biomarker Panels. Front Oncol 12:997506, 2022. e-Pub 2022. PMID: 36248987.
38. Roszik J, Mustachio LM, Livingston JA, Groisberg R, Carmagnani Pestana R, Subbiah V, Conley AP. Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers (Basel) 13(20), 2021. e-Pub 2021. PMID: 34680396.
39. Pestana RC, Roszik J, Groisberg R, Sen S, Van Tine BA, Conley AP, Subbiah V. Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Curr Probl Cancer 45(5):100794, 2021. e-Pub 2021. PMID: 34656365.
40. Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open 6(3):100113. e-Pub 2021. PMID: 33930659.
41. Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open 6(2):100079, 2021. e-Pub 2021. PMID: 33721621.
42. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
43. Tsai JW, Leung CH, Lin H, Ingram D, Khan S, Wani K, Conley AP, Rhines LD, Lazar AJ, Wang WL. Immune microenvironment in chordoma. Modern Pathology, 2021. e-Pub 2021.
44. Nassif EF, Maloney N, Conley AP, Keung EZ. Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-differentiated Liposarcoma: A Case Report. Front Med (Lausanne) 8:715939, 2021. e-Pub 2021. PMID: 34589500.
45. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, morphoproteomics, and treatment patterns of alveolar soft part sarcoma patients and response to multiple experimental therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
46. Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel) 10(3), 2020. e-Pub 2020. PMID: 32106426.
47. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
48. Raza SM, Habib A, Wang WL, Gildey PW, Conley AP, Nader ME, Hanna EY, Su SY, DeMonte F. Surgical Management of Primary Skull Base Osteosarcomas: Impact of Margin Status and Patterns of Relapse. Neurosurgery 86(1):E23-E32, 2020. e-Pub 2020. PMID: 31515560.
49. Flint JH, Coney AP, Rubin ML, Feng L, Lin PP, Moon B, Bird J, Satcher R, Lewis VO. Clear Cell Chondrosarcoma: Clinical Characteristics and Outcomes in 15 Patients. Sarcoma 2020, 2020. e-Pub 2020.
50. Ali AMR, Tsai JW, Leung CH, Lin H, Ravi V, Conley AP, Lazar AJ, Wang WL, Nathenson MJ. The immune microenvironment of uterine adenosarcomas. Clin Sarcoma Res 10:5, 2020. e-Pub 2020. PMID: 32231779.
51. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
52. Dupuis M, Shen Y, Curcio C, Meis JM, Wang WL, Amini B, Rhines L, Reuther J, Roy A, Fisher KE, Conley AP, Andrew Livingston J. Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. Clin Sarcoma Res 10:14, 2020. e-Pub 2020. PMID: 32782782.
53. Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer 7(1):296, 2019. e-Pub 2019. PMID: 31703609.
54. Bishop AJ, Bird JE, Conley AP, Roland CL, Moon BS, Satcher RL, Livingston JA, Patel S, Wang WL, Lazar AJ, Lewis VO, Lin PP, Guadagnolo BA. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. Am J Clin Oncol 42(10):744-748, 2019. e-Pub 2019. PMID: 31436747.
55. Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah V. Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31480474.
56. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(67):1-10, 2019. e-Pub 2019. PMID: 31096717.
57. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer 125(3):463-472, 2019. e-Pub 2019. PMID: 30383888.
58. van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME, JVMG B, Gelderblom H. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist 24(1):110-116, 2019. e-Pub 2019. PMID: 30082492.
59. Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform 2:1-12, 2018. e-Pub 2018. PMID: 30652536.
60. Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B. Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol 118(3):518-524, 2018. e-Pub 2018. PMID: 30109699.
61. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol 4(4):1-6, 2018. e-Pub 2018. PMID: 30241159.
62. Nathenson MJ, Conley AP, Lin H, Fleming N, Lazar A, Wang WL, Ravi V. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. Int J Gynecol Cancer 28(7):1297-1310, 2018. e-Pub 2018. PMID: 30044322.
63. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res 24(16):3845-3856, 2018. e-Pub 2018. PMID: 30018119.
64. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
65. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
66. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
67. Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu C. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol 33(10):1335.e13-1335.e15, 2017. e-Pub 2017. PMID: 28822650.
68. Livingston JA, Bugano D, Barbo A, Lin H, Madewell J, Wang WL, Lazar A, Tseng W, Roland C, Feig B, Pollack R, Conley A, Benjamin R, Patel S, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Scientific Reports 7(1). e-Pub 2017. PMID: 28928422.
69. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7(1):9519, 2017. e-Pub 2017. PMID: 28842575.
70. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. e-Pub 2017. PMID: 28424409.
71. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Patel S, Somaiah N, Conley A, Ali S, Ross J, Stephens P, Miller V, Sen S, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24), 2017. e-Pub 2017. PMID: 28424409.
72. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma 2017:7495914, 2017. e-Pub 2017. PMID: 29081684.
73. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11, 2017. e-Pub 2017. PMID: 28630682.
74. Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. PLoS One 12(4):e0176763, 2017. e-Pub 2017. PMID: 28453553.
75. Nathenson MJ, Conley AP, Lin H, Fleming N, Ravi V. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Sarcoma 2017:4680273, 2017. e-Pub 2017. PMID: 29445312.
76. Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine adenosarcoma: a review. Curr Oncol Rep 18(11):68, 2016. e-Pub 2016. PMID: 27718181.
77. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7(39):64421-64430, 2016. e-Pub 2016. PMID: 27486883.
78. Kamali F, Wang WL, Guadagnolo BA, Fox PS, Lewis VO, Lazar AJ, Conley AP, Ravi V, Toliyat M, Ladha HS, Hobbs BP, Amini B. MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumors. Br J Radiol 89(1058):20150308, 2016. e-Pub 2016. PMID: 26577289.
79. Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection. JAMA Oncol 1(6):797-805, 2015. e-Pub 2015. PMID: 26204106.
80. Raj S, Bui MM, Springett G, Conley A, Lavilla-Alonso S, Zhao X, Chen D, Haysek R, Gonzalez R, Letson GD, Finkelstein SE, Chiappori AA, Gabrilovitch DI, Antonia SJ. Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma. Sarcoma 2015:614736, 2015. e-Pub 2015. PMID: 26880867.
81. DeVito N, Henderson E, Han G, Reed D, Bui MM, Lavey R, Robinson L, Zager JS, Gonzalez RJ, Sondak VK, Letson GD, Conley A. Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. PLoS One 10(10):e0140362, 2015. e-Pub 2015. PMID: 26469269.
82. Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. J Gastrointest Cancer 45(4):431-40, 2014. e-Pub 2014. PMID: 24847952.
83. Conley AP, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. J Clin Oncol 32(32):e107-110, 2014. e-Pub 2014. PMID: 24550417.
84. de la Fuente SG, Deneve JL, Parsons CM, Zager JS, Conley AP, Gonzalez RJ. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB (Oxford) 15(9):655-60, 2013. e-Pub 2013. PMID: 23458233.
85. Jardim DL, Conley A, Subbiah V. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis 8(1):112, 2013. e-Pub 2013. PMID: 23895135.
86. Conley AP, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach. J Gastrointest Cancer 44(2):190-8, 2013. e-Pub 2013. PMID: 23229801.
87. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res 3(1):7, 2013. e-Pub 2013. PMID: 23663788.
88. Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 5(1):147-62, 2013. e-Pub 2013. PMID: 23700373.
89. Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM, Cheong D, Letson DG, Zager JS. A single institution experience with the use of isolated limb infusion for limb salvage in limb threatening extremity sarcomas. Int J Hyperthermia 29(1):1-7, 2013. e-Pub 2013. PMID: 23205633.
90. Deneve JL, Choi J, Gonzalez RJ, Conley AP, Stewart S, Han D, Werner P, Chaudhry TA, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol 35(6):1480-7, 2012. e-Pub 2012. PMID: 22699779.
91. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, Zhou K, Duensing A, Trent JC. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol 5(1):93-104, 2011. e-Pub 2011. PMID: 21115411.
92. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Zhou K, Wang WL, Duensing A, Trent J. Synergistic Induction of Apoptosis by the Bcl-2 Inhibitor ABT-737 and Imatinib Mesylate in Gastrointestinal Stromal Tumor Cells. Mol Oncol 5(1):93-104, 2011. e-Pub 2011.
93. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116(9):2174-9, 2010. e-Pub 2010. PMID: 20162709.
94. Wang WL, Conley AP, Reynoso D, Nolden LK, Lazar A, George S, Trent J. Mechanisms of Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor. Cancer Chemother Pharmacol 67:S15-24. e-Pub 2010.

Invited Articles

1. Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review. Expert Rev Anticancer Ther 18(11):1-8, 2018. e-Pub 2018. PMID: 30169984.
2. El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley AP. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep 20(5):37, 2018. e-Pub 2018. PMID: 29582189.
3. Conley AP, Benjamin RS. Historic Perspective and Impact of GIST: A Model for Personalized Cancer. Cancer Foundations of Clinical Cancer Research 9(1):24-26, 2010. e-Pub 2010.
4. Conley AP, Stevenson W, Garcia-Manero G. Review of the Response Criteria for Myelodysplastic Syndrome. European Haematology:30-31, 2007. e-Pub 2007.

Review Articles

1. Reid, TR, Oronsky, B, Williams, J, Caroen, S, Conley, AP. TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39461878.
2. Banu MA, Raza SM, Amini M, Seaman S, Rubino F, Snyder R, Patel S, DeMonte F, Conley AP. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol. Neurosurg Focus 56(5):E15, 2024. e-Pub 2024. PMID: 38691867.
3. Kesari S, Bessudo A, Gastman BR, Conley AP, Villaflor VM, Nabell LM, Madere D, Chacon E, Spencer C, Li L, Larson C, Reid T, Caroen S, Oronsky B, Stirn M, Williams J, Barve MA. BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. Future Oncol 18(29):3245-3254, 2022. e-Pub 2022. PMID: 35950603.
4. D'Souza MP, Adams E, Altman JD, Birnbaum ME, Boggiano C, Casorati G, Chien YH, Conley A, Eckle SBG, Früh K, Gondré-Lewis T, Hassan N, Huang H, Jayashankar L, Kasmar AG, Kunwar N, Lavelle J, Lewinsohn DM, Moody B, Picker L, Ramachandra L, Shastri N, Parham P, McMichael AJ, Yewdell JW. Casting a wider net: Immunosurveillance by nonclassical MHC molecules. PLoS Pathog 15(2):e1007567, 2019. e-Pub 2019. PMID: 30789961.
5. Nathenson MJ, Conley AP, Sausville E. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23(1):71-83, 2018. e-Pub 2018. PMID: 28935774.
6. Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep 19(12):78, 2017. e-Pub 2017. PMID: 29030741.
7. Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A. Cellular immunotherapy for soft tissue sarcomas. Immunotherapy 4(3):283-90, 2012. e-Pub 2012. PMID: 22401634.
8. Conley AP, Trent J, Zhang W. Recent progress in the genomics of soft tissue sarcomas. Curr Opin Oncol 20(4):395-9, 2008. e-Pub 2008. PMID: 18525334.

Professional Educational Materials

1. Collaborator O. Personalized Cancer Therapy Website, 2014.

Abstracts

1. Nassif EF, Beird H, Mitra A, Liu B, McBride K, Wang W, Ingram D, Wani K, Initiative Team EZKT, Team PM, Zarzour A, Conley A, Araujo D, Livingston J, Ratan R, Patel S, Ravi V, Benjamin R, Lazar AJ, Roland CL, Futreal P, Somaiah N. Histology Specific Intratumoral B-Cell Biology in Alveolar Soft-Part Sarcomas (ASPS) in Response to Durvalumab-Tremelimumab (D-T). 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
2. Torres MB, Leung CH, Keung E, Feng C, Beird H, Zarzour A, Scally C, Hunt K, Conley A, Bishop A, Guadagnolo B, Farooqi A, Mitra D, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar A, Roland CL, Somaiah N, Nassif EF. Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
3. Gingrich A, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally CP, Hunt KK, Torres KE, Roland CL, Prabhakara S, Initiative Team RT, Team PM, Futreal P, Bishop A, B Guadagnolo A, Mitra D, Farooqi A, Araujo D, Zarzour MA, Livingston JA, Conley A, Patel SR, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif EF. Leiomyosarcoma intratumoral macrophage infiltrates are associated with distinct clinical and genomic presentations. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
4. Livingston J, Cloutier J, Conley AP, Gorlick R, Benjamin RS, Posey K, Nassif E, Zarzour M, Araujo D, Ratan R, Ravi V, Somaiah N, Lin H, Leung CH, Lazar AJ, Lewis VO, Lin P, Amini B, Valenzuela RF, Patel S, Wang W. Chemotherapy and Prognostic Significance of Extent of Dedifferentiation in Dedifferentiated Parosteal Osteosarcoma. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
5. Roszik J, Denu RA, Nassif EF, Nakazawa M, Livingston JA, Ekdemir KC, Ratan R, Lazar AJ, Wang WL, Pestana R, Farooqi A, Roland C, Keung E, Ravi V, Somaiah N, Patel SR, Conley AP. TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
6. Denu RA, Joseph CP, Urquiola ES, Byrd PS, Ratan R, Zarzour MA, Conley AP, Araujo D, Ravi V, Patel S, Wang W, Lazar AJ, Somaiah N. CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
7. Conley AP, Williams J, Larson C, Oronsky B, Stirn M, Burbano E, Abrouk N, Caroen S, Reid T, Kesari S. AdAPT-001 in advanced sarcomas including chordoma (Beta Prime): A multicenter, open-label, phase 1 clinical trial (NCT04673942) & opportunities for neoadjuvant trials in chordoma. 2023 International Chordoma Research Workshop, 2023. e-Pub 2023.
8. Conley AP, Li L, MD, PhD, Livingston JA, MD, Ravi V, Bishop AJ, MD, Grosshans DR, MD, PhD, Ghia AJ, MD, Mathew G, MS, Khanduri I, Lang W, Bird JE, Alvarez-Breckenridge CA, Raza S, Rhines LD, DeMonte F, F Lazar AJ, Wang W, Aaroe A, Lin YH, Roszik P, Amini B, Yevich S, Akdemir K, Puduvalli V, Patel S. A phase 2 trial of cetuximab for patients with advanced/metastatic chordoma – interim results. International Chordoma Research Workshop, 2023. e-Pub 2023.
9. Conley AP. A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma (ETCTN 10330). 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
10. Salkeni MA, Ko B, Van Tine BA, Conley AP, Davis EJ, Burgess MA, Close JL, Foster JC, O'Sullivan Coyne GH, Moore N, Fino KK, Ferry-Galow KV, Rosenberger C, Parchment RE, Sharon E, Doroshow JH, Chen AP. A phase 2 study of an anti-PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
11. Lacuna KP, Lee SM, Ge L, Druta M, Conley AP, Keohan ML, Agulnik M, Burgess MA, Chalmers AW, D’Amato GZ, Powers B, Seetharam M, Siontis BL, Weiss MC, Bose S, Sheikh T, Piekarz R, Schwartz GK, Ingham M. Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
12. Conley AP, Roland CL, Gastman B, Villaflor VM, Larson C, Reid TR, Caroen S, Alizadeh B, Oronsky B, Stirn M, Williams J, Burbano E, Coyle A, Barve MA, Wagle N, Abrouk N, Kesari S. Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001TGF-ß Trap. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
13. Conley AP. Trial in progress: A phase 2 multicenter dose-expansion study to evaluate the safety, pharmacodynamics, and antitumor activity of AdAPT-001 plus a checkpoint inhibitor in patients with advanced solid tumors. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
14. Wilky B, Rodon J, Ingham M, Pollack S, Conley A. A Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma including Undifferentiated Pleomorphic Sarcoma. 2023 ESMO Targeted Anti-Cancer Therapies Congress, 2023. e-Pub 2023.
15. Ramirez JO, Lee Y, Rodriguez R, Tomczak K, Zhou X, Ravi V, Conley A, Ingram D, Livingston J, Ludwig J, Somaiah N, Haymaker C. Analysis of resected liposarcoma tumors identifies CD73 as a potential therapeutic target. ESMO Sarcoma and Rare Cancers, 2023. e-Pub 2023.
16. Jones RL, Chawla SP, Shepard DR, Davis EJ, Wang V, Davis LE, Wasp GT, Martin-Broto J, Stacchiotti S, Blay JV, Reichardt P, Gelderblom H, Senne L, Darling M, Bayer K, Eckelman B, Conley AP. A Randomized, Placebo-Controlled, Phase 2 Trial of Inbrx-109 in Unresectable or Metastatic Conventional Chondrosarcoma. 2022 CTOS Annual Meeting, 2022. e-Pub 2022.
17. Chawla S, Conley AP, Lieu C, Wilky BA, Tolcher AW, Chao J, Lakhani NJ, Diab M, Berz M, Senne L, O'Neill B, Fox M, Andrianov V, Eckelman B, Maki R, Subbiah V. Updated Efficacy & Safety of the Tetravalent Death Receptors against InBRX-109 in patients with Chondrosarcoma data from the Phase I Expansion Cohorts. CTOS Annual Meeting, 2022. e-Pub 2022.
18. Farooqi A, Yoder A, Pasalic D, Erasmus J, Wernz C, Mitra D, Somaiah N, Conley A, Ratan R, Livingston J, Roland C, Scally C, Keung E, Gandhi S, Guadagnolo B, Nguyen Q, Bishop A. Stereotactic ablative radiation therapy for sarcoma lung metastases: indications for treatment and patterns of failure. ASTRO Annual Meeting, 2022. e-Pub 2022.
19. Bowles DW, Bazhenova L, Hescot S, Folprecht G, Daga H, Massarelli E, Conley AP, Lamartina L, Lin J, Ahn ER, Osborne S, Heinzmann S, Carrizosa D. Entrectinib in patients with NTRK fusion-positive (NTRK-fp) thyroid cancer: updated data from STARTRK-2. 44th Annual Meeting of European Thyroid Association, 2022. e-Pub 2022.
20. Thirasastr P, Joseph C, Araujo DM, Benjamin RS, Conley AP, Livingston JA, Ludwig JA, Patel SR, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Outcomes in late-line systemic treatment in GISTs: Does sequence matter?. ASCO Annual Meeting, 2022. e-Pub 2022.
21. Nelson BN, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, Moore JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Ahnert JR, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple negative breast cancer. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
22. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, Moore JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Ahnert JR, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase IB study of selinexor and eribulin combination in advanced solid tumors and triple negative breast cancer. ASCO Annual Meeting, 2022. e-Pub 2022.
23. Conley AP, Li L, Livingston JA, Bishop AJ, Grosshanes D, Ghia A, Mathew G, Khanduri I, Lang W, Bird J, Alvarez-Breckenridge C, Raza SM, Rhines LD, DeMonte F, Lazar A, Wang WL, Aarve A, Lin H, Roszik J, Amini B, Yevich S, Levy J, Sommer J, Freed D, Akdemir KC, Pudevali V, Patel SR. A Phase 2 Trial of Cetuximab for Patients with Locally Advanced Metastatic Chordoma. 2022 CTOS Annual Meeting, 2022. e-Pub 2022.
24. Nakazawa M, Livingston J, Bishop AJ, Zarzour MA, Somaiah N, Ratan R, Gill JB, Urquiola E, Posey K, Guadagnolo BA, Gorlick RG, Benjamin RS, Patel S, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: An MD Anderson Cancer Center (MDACC) case series. 2022 Annual ASCO Meeting, 2022. e-Pub 2022.
25. Somaiah N, Livingston JA, Ravi V, Lin HY, Amini B, Solis LM, Conley AP, Zarzour MA, Ludwig JA, Ratan R, Wang WL, Araujo DM, Patel SR, Roland CL, Lazar AJ, Gorlick RG, Parra ER, Haymaker CL. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. 2022 Annual ASCO Meeting, 2022. e-Pub 2022.
26. Pestana RC, Moyers J, Hamerschlak N, Roszik J, Sen S, Hong DS, Naing A, Herzog C, Fu S, Ravi V, Patel S, Livingston J, Somaiah N, Conley AP, Meric-Bernstam F, Subbiah V. Precision Oncology In Sarcoma Drug Development: Impact Of Biomarker Matching On Outcomes In Phase I Clinical Trials. 2021 CTOS Annual Meeting, 2021. e-Pub 2021.
27. Wilky BA, Druta M, Rodón J, Conley AP, Falchook G, Burriss H, Ingham M, Mehmi I, Sievers E. Interim Safety And Efficacy Results From A Phase 1/2 Study Of Ba3011, A Cab-Axl-Adc, In Patients With Advanced Sarcoma Or Other Solid Tumors. 2021 Annual CTOS Virtual Meeting, 2021. e-Pub 2021.
28. Bishop AJ, Amini B, Lin H, Raza SM, Smith JT, Patel S, Grosshans D, Farooqi A, Guadagnolo B, Mitra D, Akdemir K, Lazar A, Wang W, Bird JE, Rhines LD, Conley AP. Immune Checkpoint Inhibitors Provide Favorable Responses In Patients With Recurrent Chordoma. 2021 CTOS Annual Virtual Meeting, 2021. e-Pub 2021.
29. Thirasastr P, Amini B, Lin H, Roland CL, Nassif EF, Zarzour A, Conley AP, Araujo DM, Keung EZ, Livingston J, Ratan R, Ludwig JA, IV, Benjamin RS, Zhou X, Patel S, Ravi V, Feig BW, Somaiah N. Retrospective Evaluation Of The Role Of Gemcitabine- Docetaxel In Well-Differentiated And Dedifferentiated Liposarcoma. 2021 CTOS Annual Meeting, 2021. e-Pub 2021.
30. Subbiah V, Conley AP, Lieu C, Wilky BA, Lakhani N, Tolcher A, Chao J, Chow W, Wagner K, Andrianov V, Heidt A, Rowell E, Eckelman B, Deveraux Q, Kalabus J, Chua-Alcala VT. Safety And Efficacy Of The Tetravalent Death Receptor 5 Agonist Inbrx-109 In Patients With Conventional Chondrosarcoma: Update From The Phase 1 Expansion Cohort. 2021 CTOS Annual Virtual Meeting, 2021. e-Pub 2021.
31. Akdemir K, Wani K, Ingram DR, Wang W, Raza SM, Bishop AJ, Alvarez-Breckenridge C, Tatsui C, Conley AP, Rhines LD, Futreal A, Lazar A. 3D Genome Structural Alterations And Oncogene Expression In Chordoma Genomes. 2021 CTOS Annual Virtual Meeting, 2021. e-Pub 2021.
32. Moyers JY, Roszik J, Pestana C, Livingston JA, Zarzour A, Ravi V, Ratan R, Somaiah N, Conley AP, Subbiah V. Examining Stripes On A Herd Of Zebras: Impact Of Genomic Matching For Ultrarare Sarcomas In Phase 1 Clinical Trials. 2021 Annual CTOS Virtual Meeting, 2021. e-Pub 2021.
33. Naqash AR, O'Sullivan-Coyne GH, Moore N, Sharon E, Takebe N, Fino KK, Ferry-Galow KV, Hu JS, Van Tine BA, Burgess MA, Read WL, Riedel RF, George S, Glod J, Conley AP, Foster JC, Fogli LK, Parchment RE, Doroshow JH, Chen AP. Phase II study of atezolizumab in advanced alveolar soft part sarcoma. 2021 ASCO Annual Virtual Meeting, 2021. e-Pub 2021.
34. Karakuzu O, Tsimberidou AM, Holley VR, Adat A, Patel SP, Sood AK, Conley AP, Urschel GE, Healey DI, O'Neill V, Janku F. Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase Study basket study. 2021 ASCO Annual Virtual Meeting, 2021. e-Pub 2021.
35. Mitra A, Somaiah N, Conley AP, Amini B, Lin H, Sanchez BE, Garcia-Prieto C, Mathew G, Bernatchez C, Ravi V, Araujo D, Zarzour MA, Livingston JA, Roland CL, Daw N, Baguley J, Wang W, Beird H, Tate T, Haymaker C, Little LD, Gumbs C, Song X, Keung EZ, Zhang S, Gite S, Zhang J, Solis L, Tawbi H, Wang L, Patel S, Benjamin RS, Lazar AJ, Wistuba II, Futreal A. Immunogenomic correlates of response to combination immune checkpoint blockade in advanced sarcoma. 2021 AACR Annual Meeting, 2021. e-Pub 2021.
36. Chawla SP, Lakhani N, Tolcher A, Lieu C, Wilky BA, Wagner KW, Heidt A, Eckelman B, Deveraux Q, Kalabus J, Conley AP, Subbiah V. Results From The Chondrosarcoma Phase 1 Study Expansion Cohort Of The Tetravalent Death Receptor 5 Agonist Inbrx-109. 2020 CTOS Annual Virtual Meeting, 2020. e-Pub 2020.
37. Chawla SP, Paz-Ares L, Patel MR, Buchschacher GL, Cheng A, Chiorean E, Chung CH, Conley AP, Garrido-Laguna I, Goto K, Hooberman AL, Hu J, Krauss JC, Krzakowski M, Loong H, Otterson GA, Ross HJ, Steuer C, Taylor MH, Trigo J, Wolf J, Brunello A, Osborne S, Simmons B, Liu SV. An Updated Analysis Of The Clinical Efficacy And Safety Of Entrectinib In Ntrk Fusion-Positive (Ntrk-Fp) Sarcoma. 2020 CTOS Annual Virtual Meeting, 2020. e-Pub 2020.
38. Subramaniam A, Zheng J, Yalamanchili S, Conley AP, Ratan R, Somaiah N, Livingston JA, Zarzour MA, Araujo DM, Benjamin RS, Patel SR, Ravi V. Modulation of YAP/TAZ by Statins to Improve Survival in Epitheloid Hemangioendothelioma (EHE). 2020 ASCO Annual Meeting, 2020. e-Pub 2020.
39. Somaiah N, Conley AP, Lin H, Amini B, Sabir SH, Araujo D, Benjamin RS, Livingston JA, Patel SR, Ratan R, Ravi V, Zarzour M, Wang WL, Taylor T, Roland C, Daw N, Futreal A, Lazar AJ, Wistuba I. A Phase II Multi-Arm Study of Durvalumab and Tremelimumab for Advanced or Metastatic Sarcomas. 2020 ASCO Annual Virtual Meeting, 2020. e-Pub 2020.
40. Groisberg R, Hong D, Holla V, Janku F, Piha-Paul S, Ravi S, Benjamin R Patel S, Somaiah N, Conley A, Siraj A, Schrock A, Ross J, Stephens P, Miller V, Sen S Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Ann Oncol, 2020. e-Pub 2020.
41. Conley AP. Patient-reported Outcomes (PROs) From Patients (Pts) with NTRK Fusion-Positive (NTRK-fp) Solid Tumours Receiving Entrectinib in the Global Phase 2 STARTRK-2 Study. ESMO Congress 2020, 2020. e-Pub 2020.
42. Parkes AM, Patel S, Leung CH, Lin HY, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Livingston JA, Ravi V, Benjamin RS, Ratan R. Systemic therapy regimen outcomes in metastatic phyllodes tumors of the breast. J. Clin Oncol 36, 2018. e-Pub 2018.
43. Groisberg R, Hess KR, Hong DS, Heymach J, Naing A, Piha-Paul SA, Janku F, Javle MM, I-Nan Hu M, Conley AP, Meric-Bernstam F, Subbiah A, V. Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials. Journal of Clinical Oncology 36(15), 2018. e-Pub 2018.
44. Somaiah N, Conley A, Espiridion BS, Lin H, Amini B, Ravi V, Araujo D, Benjamin R, Patel S, Zarzour A, Sabir S, Lazar AJ, Wang WL, Wistuba II, Hwu P. A phase II multi-arm study to test the efficacy of durvalumab and tremelimumab in multiple sarcoma subtypes. CTOS 2017 Annual Meeting, 2017. e-Pub 2017.
45. Janku F, De Groot JF, Javle MM, Pena-Prado M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Broaddus R, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. Journal of Clinical Oncology 35, 2017. e-Pub 2017.
46. Conley AP, Livingston JA, Ravi V, Shaw KR, Subbiah V, Janku F, Broaddus R, Lewis V, Patel S, Benjamin R, Wang WL, Lazar A, Futreal A, Meric-Bernstam F, Roszik J. Assessment of next generation sequencing (NGS) for patients with chondrosarcoma. CTOS 2017 Annual Meeting, 2017. e-Pub 2017.
47. Roszik J, Subbiah V, Livingston JA, Somaiah N, Ravi V, Wang WL, Yee C, Futreal PA, Lazar A, Conley AP. Next generation sequencing identifies immunotherapy targets in soft tissue sarcoma. CTOS 2017 Annual Meeting, 2017. e-Pub 2017.
48. Livingston JA, Posey K, Subbiah V, Daw JC, Somaiah N, Ravi V, Patel S, Benjamin RS, Wang WL, Lazar A, Broaddus R, Meric-Bernstam F, Shaw KR, Roszik J, Conley AP. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. Journal of Clincal Oncology:35, 2017. e-Pub 2017.
49. Nathenson M, Conley AP, Ratan R, Zarzour MA, Somaiah N, Araujo DM, Patel S, Benjamin RS, Ravi V. Efficacy of front-line chemotherapy for recurrent/metastatic adenosarcoma of the uterus. J Clin Oncol, 2016. e-Pub 2016.
50. Groisberg R, Hong DS, Janku F, Piha-Paul SA, RAvi V, Benjamin RS, Patel S, Somaiah N, COnley AP, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical next generation sequencing in sarcomas. J Clin Oncol, 2016. e-Pub 2016.
51. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Ravi V, Arauo DM, Zarzour MA, Ludwig JA, Wang WL, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. J Clin Oncol, 2016. e-Pub 2016.
52. Roszik J, Wang WL, Ravi V, Hwu P, Yee C, Futreal A, Lazar A, Conley AP. Expression and clinical correlations of PRAME in sarcoma subtypes. J Clin Oncol, 2016. e-Pub 2016.
53. Subbiah V, Murthy R, Hong D, Brown RE, Prins R, HOsing C, McGuire M, Naing A, Fu S, Chou T, Lin Q, Guevarra RP, COnley A, Kaur I, Meric-Bernstam F, Bosch M. Clinical and immunopathological effects following image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers. Cancer Research 75, 2015. e-Pub 2015.
54. Vadhan-Raj S, Ravi V, Zhou X, Araujo DM, Somaiah N, Conley AP, Daniel M, Benjamin RS, Patel S, Spasojevic I. Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study. J Clin Oncol, 2015. e-Pub 2015.
55. Subbiah V, Murthy R, Hong D, Prins R, Hosing C, Brown R, McGuire M, Naing A, Fu S, Conley A, Kaur I, Hendricks K, Kolli D, Noffsinger L, Bosch M. Safety, feasibility, and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial. Journal fo ImmunoTherapy of Cancer:199, 2015. e-Pub 2015.
56. Somaiah N, Berid H, Shaw KR, Wang WL, Conley AP, Ravi V, Torress KE, Ingram D, Roland CL, Subbiah V, Feig BW, Lazar AJF, Benjamin RS, Patel S, Hwu P, Futreal A, Meric-Bernstam F, Hong DS. Targeted next generation sequencing in well-differentiated/dedifferentiated liposrcoma (WD/DD LPS): Multiple gene amplifications but few mutations. J Clin Oncol, 2015. e-Pub 2015.
57. Conley AP, Rl S, Wang WL, Lazar AJF, Fox PS, Lin PP, Moon B, Bird JE, Araujo DM, Ravi V, Somaiah N, Patel S, Benjamin RS, Lewis VO. Clinical Characteristics and treatment outcomes of clear cell chondrosarcomas: MD Anderson Cancer Center Series. J Clin Oncol, 2015. e-Pub 2015.
58. Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig HA, Anderson PM, Araujo DM, Ravi V, Conley AP Somaiah N, Wang WL, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: the clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, 2014. e-Pub 2014.
59. Subbiah V, Patel S, Benjamin RS, Agarwal R, Janku F, Ludwig J, Anderson PM, Arujo D, Ravi V, Conley AP, Somaiah N, Naing A, Hong DS, Maric-Bernstam F. Target-based therapeutic matching in early-phase clinical trials in patients with advanced sarcoma. CTOS 2014 Annual Meeting, 2014. e-Pub 2014.
60. Ravi V, Ramesh N, Conley AP, Somaiah N, Subbiah V, Lazar A, Benjamin RS, Patel S. Prediciting survival usi FDG-PET responses in patients with unclassified sarcoma. CTOS 2014 Annual Meeting, 2014. e-Pub 2014.
61. Somaiah N, Pollack SM, Wei W, Araujo D, Amaria RN, Mittendorf EA, Conley AP, Ravi V, Subbiah V, Benjamin RS, Patel S, Kenney R, Hsu F, Hwu P, Jones RL, Shapiro G, Kim JW, Block MM. Evaluating the safety and immunogenicity of ID-LV305, a third generation lentiviral vaccine in patients with NY-ESO-1 positive malignancies. CTOS 2014 Annual Meeting, 2014. e-Pub 2014.
62. Conley AP, Wang WL, Ravi V, Somaiah N, Subbiah V, Lazar A, Benjamin RS, Patel S. Clinical outcomes for patients with metastatic, malignant granular cell tumors treated with systemic therapies. CTOS 2014 Annual Meeting, 2014. e-Pub 2014.
63. Vadhan-Raj S, Zhou X, Araujo DM, Somaiah N, Conley AP, Ravi V, Daniel M, Benjamin RS, Patel S. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receivig multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosfamide (AI): randomized cross-over study. J Clin Oncol, 2014. e-Pub 2014.
64. Raj SKS, Indelicato DJ, Chiappori A, COnley AP, Gonzales R, Heysec R, Letson DD, Gabrilovich D, Bui MM, Finkelstein S, Antonia SJ. Neoadjuvant administration of radiation therapy and intratumoral autologous dendritic cells in patients with localized high-risk soft tissue sarcomas. J Clin Oncol, 2014. e-Pub 2014.
65. Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ. Assessment and management o the risk of recurrence of resected astrointestinal stromal tumors. J Clin Oncol, 2014. e-Pub 2014.
66. Guerin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu E, Conley AP. Association between risk of recurrence assessment and adjuvant treatment (Tx) duration in patients (pts) with resected gastrointestinal stromal tumor. Annals of Oncology, 2014. e-Pub 2014.
67. Livingston JA, Bugano D, Madewell J, Wang WL, Conley AP, RAvi V, Araujo D, Tsen WW, Feig B, Toress KE, Benjamin RS, Patel S, Somaiah N. Assessing chemotherapy benefit in well-differentiated/de-differentiated liposarcoma. CTOS 2014 Annual Meeting, 2014. e-Pub 2014.
68. Somaiah N, Gomez DBD, Madewell JE, Wang WL, Conley AP, Ravi V, Araujo DM, Ludwig JA, Benjamin RS, Patel S. Defining the chemotherapy (CT) response in well-differentiated CT response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the etroperitoneum (RP): A tertiary referral cancer center experience. J Clin Oncol, 2014. e-Pub 2014.
69. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Zarzour MA, Ingram D, Little L, Protopopov A, Lazar AJF, Araujo DM, Tores KE, Patel S, Zhang J, Ali SM, Miller VA, Stephens PJ, Benjamin RS, Hwu P, Futreal A. Whole-exome and targeted sequencing of angiosarcomas: target identification and treatments implications. J Cllin Oncol, 2014. e-Pub 2014.
70. Dalia S, Conley AP, Fisher K, Lee JH, Wehham RM, Apte S, Gonzalez RJ. Clinicopathologic predictors (CP) of survival in patients with endometrial stromal sarcomas (ESS) treated with multimodality therapy. J Clin Oncol, 2013. e-Pub 2013.
71. Conley AP, Guerin A, Sasane M, Gautheir G, Schwiep FA, Keir CH, Magestro M, Wu EQ. Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis. J Clin Oncol, 2013. e-Pub 2013.
72. Jones RL, Berry DA, Chawla SP, Chmeilowski B, Wagner A, Sm P, COnley AP, Reed D, Shin CR, Weil SC, Heyburn J, Schulert L, Hulstine AM, Maki RG. Part 1 of a multicenter, two-part, phase II study of the safety and efficacy of the combination of gemcitabine and docetaxel with MORAB-004 in metastatic soft tissue sarcoma. CTOS 2013 Annual Meeting, 2013. e-Pub 2013.
73. Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP. Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract based approach. J Clin Oncol, 2013. e-Pub 2013.
74. Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP. Prescribing decision drivers in patients with recurrent gastrointestinal stromal tulor (GIST) previoulsy treated with adjuvant imatinib: A retrospective chart extract-based approach. J Clin Oncol, 2013. e-Pub 2013.
75. Conley AP, Ferry-Galow, Fino KK, Coyne G, Moore N, Sharon E, Burgess M, Chen J, Davis EJ, Merriam P, Razak AR, Vine Tine B, Foster JC, Takebe N, Rosenberger CL, Doroshow JH, Chen AP, Parchment RE. Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma. AACR Annual Meeting.
76. Conley AP, Ravi V, Roland CL, Reid TR, Larson C, Caroen S, Williams JA, Oronsky B, Stirn M, Abrouk N, Burbano E, Kennedy LB. Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers. 2024 ASCO Annual Meeting.
77. Lacuna KP, Ingham M, Chen L, Das B, Lee SM, Ge L, Druta M, Conley AP, Keohan ML, Agulnik M, Burgess MA, Chalmers AW, D'Amato GZ, Powers B, Seetharam M, Siontis BL, Pelosof LC, Van Tine BA, Schwartz GK, Weiss MC. Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS). 2024 Annual ASCO Meeting.
78. Denu RA, Segura RL, Farooqi AS, Ingram D, Wani KM, Cai Y, Torres KE, Keung E, Roland CL, Somaiah N, Ying H, Huse JT, Rai K, Conley AP, Patel S, Wang WL, Lazar AJ, Haddad-Nassif EF. Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes. 2024 ASCO Annual Meeting.
79. Gounder MM, Rosen E, Parikh AR, Conley AP, Hong DS, Sheth S, Mai N, Sgroe E, Mitchell R, Picard R, Brail LH, Cote GM. Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma. 2024 Annual ASCO Meeting.
80. Nash A, Ratan R, Somaiah N, Conley AP, Lewis VO, Wang WL, Lin HY, Daw NC, Gill JB, Harrison DJ, Gorlick RG, Patel S, Livingston JA. Harmonizing cancer care delivery for AYAs with osteosarcoma: Comparison of pediatric and medical oncology approaches in a single center. 2024 ASCO Annual Meeting.
81. Munnangi P, King BL, Chiang Y, Conley AP, Araujo DM, Livingston J, Ludwig JA, Nakazawa M, Nassif Haddad EF, Ravi V, Ratan R, Zarzour MA, Patel S, Torres KE, Somaiah N. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). 2024 ASCO Annual Meeting.
82. Gingrich A, Beird H, Segura RL, Denu R, Nakazawa M, Ratan R, Livingston J, Zarzour MA, Conley AP, Somaiah N, Araujo DM, Patel S, Roland CL, Futreal A, Lazar AJ, Keung EZ, Nassif Haddad EF, Initiative Team RT, Team PM. Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas. 2024 ASCO Annual Meeting.
83. Wu X, Ledbetter D, de Almeida RA, Singh S, Conley A, Wang W, Lazar A, Lang F, Gomez-Manzano C, Fueyo J, Alvarez-Breckenridge C. EXTH-67. ONCOLYTIC ADENOVIRAL INFECTION OF CHORDOMA ACHIEVES TREATMENT EFFICACY THROUGH IMMUNOGENIC CELL DEATH AND TUMOR MICROENVIRONMENT ALTERATION. Society for Neuro-Oncology 26(Supplement 8):viii252.
84. Conley AP, Reid T, Larson C, Oronsky B, Caroen S, Stirn M, Burbano E, Abrouk N, Roland CL, Williams J, Kennedy LB. Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +/- a checkpoint inhibitor 84.
85. Grachev D, Ivanov D, Kushnarev V, Yong ST, Kotlov N, Chernyshov K, Bagaev A, Fowler NH, Conley AP, Cote GM, Chawla SP. Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas. 2024 ASCO Annual Meeting.

Book Chapters

1. Livingston JA, Conley AP, Ravi V, Patel SR. In: Chapter 42: Soft tissue and bone sarcomas, The MD Anderson Manual of Medical Oncology, 3rd edition. McGraw Hill, 2022.
2. Subbiah V, Roszik J, Conley A. In: Handbook of Targeted Cancer Therapy and Immunotherapy. Wolters Kluwer, 2018.
3. Conley AP, Ravi V, Patel S. Targeted Therapy in Solid Tumors: Sarcomas. In: Targeted Therapy in Translational in Cancer Research. John Wiley & Sons, Inc, 2016.
4. Livingston JA, Conley A, Ravi V, Patel S. The MD Anderson Manual of Medical Oncology. In: Soft Tissue and Bone Sarcomas. Third. McGraw Hill Medical, 2015.
5. Subbiah V, Conley A. In: Sarcoma Chapter. Handbook of Targeted Cancer Therapy. Philadelphia, PA: Wolters Kluwer, 2014.
6. Henderson-Jackson E, Conley A, Bui MM. Molecular Pathology of bone and soft tissue neoplasms and potential targets for novel therapy. In: Cancer Growth and Progression. In: Chapter 13. Springer, 2012.
7. Conley, AP, Park MS, Trent J, Patel S. Chapter 40: Soft-Tissue and Bone Sarcomas. In: The MD Anderson Manual of Medical Oncology. McGraw Hill Medical, 2010.

Letters to the Editor

1. Conley AP, Oronsky B, Caroen S, Larson C, Reid T. Predicting the Abscopal Phenomenon-Letter to the Editor. Mol Cancer Ther 23: 248-249, 2024.